Pharmacoeconomics and Related Patient Outcomes of Multi-dose Intravenous Acetaminophen (OFIRMEV)

• Status: Completed
• Trial end date: 2018-03-01
• Target enrollment: 0
• Participant gender: Male

Summary

To examine pharmacoeconomics of IV acetaminophen (Ofirmev). Specifically, to examine its potential to improve hospital efficiency and patient outcomes. The investigators compare the addition of IV acetaminophen versus placebo on postoperative anesthesia care unit recovery times, inpatient hospital length of stay (LOS), postoperative pain scores, consumption of opiates as rescue agents and side effects among patients undergoing robotic-assisted laparoscopic prostatectomy (RALP).

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Brigham and Women's Hospital
• Collaborator: Mallinckrodt
• Treatments: Acetaminophen

Criteria

Inclusion Criteria:

• Patients undergoing robotic-assisted laparoscopic prostatectomy

• ≥18 years old males

• American Society of Anesthesiologists class 1-4

Exclusion Criteria:

• Chronic opiate use

• Liver disease (known history of hepatitis B or C, cirrhosis, nonalcoholic steatohepatitis, history of alcoholism, liver function test results greater than 3 times upper limit of normal in the past 3 months)

• Allergy/hypersensitivity to acetaminophen

• Patients with baseline dementia

• Chronic diathesis

• Chronic kidney disease